vs

Side-by-side financial comparison of UNITY BANCORP INC (UNTY) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $27.6M, roughly 1.3× Zymeworks Inc.). UNITY BANCORP INC runs the higher net margin — 43.9% vs -71.0%, a 114.9% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 24.2%). UNITY BANCORP INC produced more free cash flow last quarter ($44.3M vs $-31.8M).

Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

UNTY vs ZYME — Head-to-Head

Bigger by revenue
UNTY
UNTY
1.3× larger
UNTY
$35.3M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+48.4% gap
ZYME
72.6%
24.2%
UNTY
Higher net margin
UNTY
UNTY
114.9% more per $
UNTY
43.9%
-71.0%
ZYME
More free cash flow
UNTY
UNTY
$76.2M more FCF
UNTY
$44.3M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
UNTY
UNTY
ZYME
ZYME
Revenue
$35.3M
$27.6M
Net Profit
$15.5M
$-19.6M
Gross Margin
Operating Margin
55.8%
-80.1%
Net Margin
43.9%
-71.0%
Revenue YoY
24.2%
72.6%
Net Profit YoY
34.5%
34.3%
EPS (diluted)
$1.52
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
UNTY
UNTY
ZYME
ZYME
Q4 25
$35.3M
Q3 25
$32.8M
$27.6M
Q2 25
$34.4M
$48.7M
Q1 25
$29.4M
$27.1M
Q4 24
$28.4M
$31.0M
Q3 24
$27.7M
$16.0M
Q2 24
$25.5M
$19.2M
Q1 24
$25.6M
$10.0M
Net Profit
UNTY
UNTY
ZYME
ZYME
Q4 25
$15.5M
Q3 25
$14.4M
$-19.6M
Q2 25
$16.5M
$2.3M
Q1 25
$11.6M
$-22.6M
Q4 24
$11.5M
$-23.5M
Q3 24
$10.9M
$-29.9M
Q2 24
$9.5M
$-37.7M
Q1 24
$9.6M
$-31.7M
Operating Margin
UNTY
UNTY
ZYME
ZYME
Q4 25
55.8%
Q3 25
57.5%
-80.1%
Q2 25
62.6%
-1.4%
Q1 25
52.6%
-94.5%
Q4 24
51.0%
-71.6%
Q3 24
52.7%
-213.8%
Q2 24
49.3%
-222.9%
Q1 24
50.0%
-376.9%
Net Margin
UNTY
UNTY
ZYME
ZYME
Q4 25
43.9%
Q3 25
43.8%
-71.0%
Q2 25
48.0%
4.8%
Q1 25
39.5%
-83.5%
Q4 24
40.5%
-75.8%
Q3 24
39.4%
-186.6%
Q2 24
37.1%
-195.8%
Q1 24
37.5%
-315.6%
EPS (diluted)
UNTY
UNTY
ZYME
ZYME
Q4 25
$1.52
Q3 25
$1.41
$-0.26
Q2 25
$1.61
$0.03
Q1 25
$1.13
$-0.30
Q4 24
$1.13
$-0.32
Q3 24
$1.07
$-0.39
Q2 24
$0.92
$-0.49
Q1 24
$0.94
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
UNTY
UNTY
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$345.6M
$320.1M
Total Assets
$3.0B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
UNTY
UNTY
ZYME
ZYME
Q4 25
Q3 25
$64.8M
Q2 25
$98.3M
Q1 25
$76.2M
Q4 24
$66.1M
Q3 24
$122.4M
Q2 24
$71.0M
Q1 24
$114.8M
Total Debt
UNTY
UNTY
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$230.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
UNTY
UNTY
ZYME
ZYME
Q4 25
$345.6M
Q3 25
$334.0M
$320.1M
Q2 25
$319.8M
$334.5M
Q1 25
$306.1M
$325.0M
Q4 24
$295.6M
$338.8M
Q3 24
$284.3M
$367.0M
Q2 24
$273.4M
$406.2M
Q1 24
$266.8M
$438.0M
Total Assets
UNTY
UNTY
ZYME
ZYME
Q4 25
$3.0B
Q3 25
$2.9B
$397.3M
Q2 25
$2.9B
$408.4M
Q1 25
$2.8B
$425.5M
Q4 24
$2.7B
$463.1M
Q3 24
$2.6B
$487.2M
Q2 24
$2.6B
$515.6M
Q1 24
$2.6B
$553.8M
Debt / Equity
UNTY
UNTY
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
UNTY
UNTY
ZYME
ZYME
Operating Cash FlowLast quarter
$44.9M
$-31.4M
Free Cash FlowOCF − Capex
$44.3M
$-31.8M
FCF MarginFCF / Revenue
125.7%
-115.2%
Capex IntensityCapex / Revenue
1.6%
1.5%
Cash ConversionOCF / Net Profit
2.90×
TTM Free Cash FlowTrailing 4 quarters
$81.7M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
UNTY
UNTY
ZYME
ZYME
Q4 25
$44.9M
Q3 25
$45.5M
$-31.4M
Q2 25
$-25.3M
$12.1M
Q1 25
$17.9M
$-3.4M
Q4 24
$48.0M
$-41.5M
Q3 24
$17.7M
$-5.9M
Q2 24
$-8.4M
$-25.0M
Q1 24
$15.8M
$-37.7M
Free Cash Flow
UNTY
UNTY
ZYME
ZYME
Q4 25
$44.3M
Q3 25
$45.3M
$-31.8M
Q2 25
$-25.5M
$11.6M
Q1 25
$17.6M
$-3.4M
Q4 24
$47.3M
$-41.8M
Q3 24
$17.5M
$-6.8M
Q2 24
$-8.6M
$-25.6M
Q1 24
$15.7M
$-37.9M
FCF Margin
UNTY
UNTY
ZYME
ZYME
Q4 25
125.7%
Q3 25
138.1%
-115.2%
Q2 25
-74.2%
23.7%
Q1 25
59.9%
-12.6%
Q4 24
166.5%
-134.8%
Q3 24
63.3%
-42.4%
Q2 24
-33.7%
-133.0%
Q1 24
61.4%
-377.5%
Capex Intensity
UNTY
UNTY
ZYME
ZYME
Q4 25
1.6%
Q3 25
0.7%
1.5%
Q2 25
0.5%
1.1%
Q1 25
1.0%
0.1%
Q4 24
2.4%
1.0%
Q3 24
0.5%
5.6%
Q2 24
0.5%
3.1%
Q1 24
0.3%
1.8%
Cash Conversion
UNTY
UNTY
ZYME
ZYME
Q4 25
2.90×
Q3 25
3.16×
Q2 25
-1.54×
5.21×
Q1 25
1.54×
Q4 24
4.17×
Q3 24
1.62×
Q2 24
-0.89×
Q1 24
1.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons